Inovio is bringing IMMUNO-INGENUITY to life and reshaping the future of treating and preventing cancer and infectious diseases.
POTENTIAL HPV IMMUNOTHERAPY TREATMENT:
GLOBAL PHASE 3
Clinical Trial – HPV303: Revealing New Treatment Possibilities
Leading the way in activation immunotherapy
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Inovio's technology is IMMUNO-INGENUITY in action
Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.